4D pharma plc (LON:DDDD), a pharmaceutical company leading the development of live biotherapeutics, has today announced that data from the Company’s completed Phase Ib double-blind placebo-controlled clinical study of Blautix, the Company’s live biotherapeutic for the treatment of Irritable Bowel Syndrome (IBS), in healthy individuals and IBS subjects will be presented today in a poster session at the 2018 Digestive Disease Week meeting in Washington DC. The Company has previously announced the topline results from this study.
The data presented show that Blautix was safe and well tolerated. More IBS subjects who received Blautix (82%) showed an overall improvement in IBS symptom scores compared to subjects receiving placebo (50%), and Blautix treatment increased microbiota diversity and stability.
Dr. Alex Stevenson, 4D Pharma Plc Chief Scientific Officer, commented: “The data from this first clinical trial of Blautix has provided a strong foundation for further clinical development as we progress into larger studies. Following the clearing of our Investigational New Drug Application by the U.S. Food and Drug Administration, we are now working with clinical sites in the US and Europe to prepare for the commencement of the upcoming Blautix Phase II trial, which we will begin enrolling later this year.”
